Utah Retirement Systems Boosts Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Posted by on Mar 13th, 2023

Utah Retirement Systems raised its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) by 0.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,971 shares of the biotechnology company’s stock after buying an additional 100 shares during the period. Utah Retirement Systems’ holdings in Sarepta Therapeutics were worth $1,654,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Hanseatic Management Services Inc. purchased a new stake in Sarepta Therapeutics during the third quarter valued at about $35,000. Cullen Frost Bankers Inc. purchased a new stake in shares of Sarepta Therapeutics during the third quarter worth about $44,000. Altshuler Shaham Ltd purchased a new stake in shares of Sarepta Therapeutics during the third quarter worth about $58,000. C M Bidwell & Associates Ltd. boosted its holdings in shares of Sarepta Therapeutics by 1,966.7% during the second quarter. C M Bidwell & Associates Ltd. now owns 620 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 590 shares during the period. Finally, Nkcfo LLC purchased a new stake in shares of Sarepta Therapeutics during the third quarter worth about $85,000. 87.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Oppenheimer dropped their target price on shares of Sarepta Therapeutics from $180.00 to $150.00 and set an “outperform” rating for the company in a report on Thursday. The Goldman Sachs Group increased their price target on shares of Sarepta Therapeutics from $171.00 to $190.00 and gave the stock a “buy” rating in a research note on Wednesday, March 1st. JPMorgan Chase & Co. increased their price target on shares of Sarepta Therapeutics from $153.00 to $206.00 and gave the stock an “overweight” rating in a research note on Friday, March 3rd. Cantor Fitzgerald raised their target price on shares of Sarepta Therapeutics from $150.00 to $174.00 in a research note on Tuesday, December 13th. Finally, SVB Leerink reaffirmed an “outperform” rating and set a $160.00 target price on shares of Sarepta Therapeutics in a research note on Friday, January 20th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $171.60.

Sarepta Therapeutics Trading Down 3.0 %

Shares of Sarepta Therapeutics stock opened at $143.92 on Monday. The company’s fifty day simple moving average is $127.84 and its 200-day simple moving average is $119.26. The stock has a market capitalization of $12.66 billion, a PE ratio of -17.92 and a beta of 0.97. Sarepta Therapeutics, Inc. has a 1-year low of $61.28 and a 1-year high of $159.84. The company has a debt-to-equity ratio of 4.01, a current ratio of 4.13 and a quick ratio of 3.80.

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last issued its quarterly earnings results on Tuesday, February 28th. The biotechnology company reported ($1.24) earnings per share for the quarter, topping the consensus estimate of ($1.28) by $0.04. The business had revenue of $258.43 million for the quarter, compared to analysts’ expectations of $250.51 million. Sarepta Therapeutics had a negative net margin of 75.40% and a negative return on equity of 117.29%. The company’s revenue was up 28.3% compared to the same quarter last year. During the same quarter last year, the company posted ($1.42) EPS. As a group, equities analysts anticipate that Sarepta Therapeutics, Inc. will post -4.37 earnings per share for the current year.

Sarepta Therapeutics Profile

(Get Rating)

Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Featured Stories

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.